BIM
ALNY icon

BlackRock Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

BlackRock Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$1.38M Sell
36,732
-13,139
-26% -$550K ﹤0.01% 2479
2016
Q3 		$3.38M Sell
49,871
-4,185
-8% -$295K ﹤0.01% 1766
2016
Q2 		$3M Buy
54,056
+11,114
+26% +$700K ﹤0.01% 1808
2016
Q1 		$2.69M Buy
42,942
+2,278
+6% +$151K ﹤0.01% 1792
2015
Q4 		$3.83M Sell
40,664
-481
-1% -$44.6K ﹤0.01% 1585
2015
Q3 		$3.31M Sell
41,145
-4,268
-9% -$474K ﹤0.01% 1675
2015
Q2 		$5.44M Buy
45,413
+12,621
+38% +$1.51M 0.01% 1425
2015
Q1 		$3.42M Buy
32,792
+8,996
+38% +$912K ﹤0.01% 1659
2014
Q4 		$2.31M Sell
23,796
-503
-2% -$46.6K ﹤0.01% 1926
2014
Q3 		$1.9M Sell
24,299
-344
-1% -$22.2K ﹤0.01% 2032
2014
Q2 		$1.56M Sell
24,643
-138,082
-85% -$8.21M ﹤0.01% 2289
2014
Q1 		$10.9M Buy
162,725
+935
+0.6% +$72.4K 0.02% 868
2013
Q4 		$10.4M Sell
161,790
-3,956
-2% -$236K 0.02% 886
2013
Q3 		$10.6M Buy
165,746
+9,505
+6% +$474K 0.02% 808
2013
Q2 		$4.84M Buy
+156,241
New +$4.16M 0.01% 1238

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Investment Management's ALNY Position: Q4 2016 in Review

BlackRock Investment Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 26% in Q4 2016, selling an estimated $550K and leaving 36,732 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #2479.

BlackRock Investment Management first reported a position in ALNY in Q2 2013 and has held it in 15 quarters since. The position peaked at $10.9M in Q1 2014. 210 funds tracked by Wall St. Rank hold ALNY as of Q4 2016.

  • BlackRock Investment Management held 36,732 shares of Alnylam Pharmaceuticals worth $1.38M as of Q4 2016.
  • BlackRock Investment Management sold 13,139 Alnylam Pharmaceuticals shares in Q4 2016, an estimated $550K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2479 holding.
  • BlackRock Investment Management first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Investment Management's Alnylam Pharmaceuticals position peaked at $10.9M in Q1 2014.
  • 210 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.